Cargando…
Is It Time to Genotype Beyond HPV16 and HPV18 for Cervical Cancer Screening?
Autores principales: | Chua, Brandon Wen Bing, Ma, Viva Yan, Alcántar-Fernández, Jonathan, Wee, Hwee Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134213/ https://www.ncbi.nlm.nih.gov/pubmed/35645701 http://dx.doi.org/10.3389/ijph.2022.1604621 |
Ejemplares similares
-
Health care provider's experience and perspective of cervical cancer screening in Singapore: A qualitative study
por: Chua, Brandon Wen Bing, et al.
Publicado: (2022) -
Cost-Effectiveness Analysis of HPV Extended versus Partial Genotyping for Cervical Cancer Screening in Singapore
por: Chua, Brandon, et al.
Publicado: (2023) -
HPV16/18 genotyping for the triage of HPV positive women in primary cervical cancer screening in Chile
por: Lagos, Marcela, et al.
Publicado: (2015) -
Primary Screening for Cervical Cancer Based on High-Risk Human Papillomavirus (HPV) Detection and HPV 16 and HPV 18 Genotyping, in Comparison to Cytology
por: Agorastos, Theodoros, et al.
Publicado: (2015) -
Comparison of cycle threshold values of the Cobas HPV test and viral loads of the BMRT HPV test in cervical cancer screening
por: Yang, Qing, et al.
Publicado: (2022)